Views

CrossRef citations to date

Altmetric

Original Research

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

Chetan S KaryekarBristol-Myers Squibb, Princeton, NJ, USACorrespondence[email protected]

Shoba RavichandranBristol-Myers Squibb, Princeton, NJ, USA

Elsie AllenBristol-Myers Squibb, Princeton, NJ, USA

Douglas FlemingBristol-Myers Squibb, Princeton, NJ, USA

Robert FrederichBristol-Myers Squibb, Princeton, NJ, USA

Figures & data

Table 1 Pivotal phase III Studies (24 Weeks) of saxagliptin in patients with type 2 diabetes mellitus

Download CSV Display Table

Table 2A Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Download CSV Display Table

Table 2B Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22

Download CSV Display Table

Table 3A Glycemic efficacy at 24 weeks in older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Download CSV Display Table

Table 3B Glycemic efficacy at 24 weeks in older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22

Download CSV Display Table

Table 4A Adverse events in older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Download CSV Display Table

Table 4B Adverse events in older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22

Download CSV Display Table

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

Table 1 Pivotal phase III Studies (24 Weeks) of saxagliptin in patients with type 2 diabetes mellitus

Table 2A Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Table 2B Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22

Table 3A Glycemic efficacy at 24 weeks in older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Table 3B Glycemic efficacy at 24 weeks in older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22

Table 4A Adverse events in older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Table 4B Adverse events in older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

Figures & data

Table 1 Pivotal phase III Studies (24 Weeks) of saxagliptin in patients with type 2 diabetes mellitus

Table 2A Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapyCitation18–Citation21,Citation24

Table 2B Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapyCitation22

Table 3A Glycemic efficacy at 24 weeks in older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapyCitation18–Citation21,Citation24

Table 3B Glycemic efficacy at 24 weeks in older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapyCitation22

Table 4A Adverse events in older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapyCitation18–Citation21,Citation24

Table 4B Adverse events in older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapyCitation22

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 2A Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Table 2B Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22

Table 3A Glycemic efficacy at 24 weeks in older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Table 3B Glycemic efficacy at 24 weeks in older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22

Table 4A Adverse events in older and younger patients with type 2 diabetes mellitus from five pooled studies of saxagliptin vs placebo as monotherapy and as add-on therapy^Citation18^–^{Citation21,Citation24}

Table 4B Adverse events in older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy^Citation22